While the rest of Wall Street stayed busy chasing the next artificial intelligence (AI) chip darling, Stanley Druckenmiller was doing what he does best, picking winners before the crowd even catches on.
Through his Duquesne Family Office, Druckenmiller scooped up 1.89 million shares of Caris Life Sciences (CAI) during Q1 FY2026, a precision medicine company most investors have never come across, parking $33.87 million into the position.
